Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 5 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients With Diabetic Nephropathy

Trial Profile

Randomised, Double-blind, Placebo-controlled (Within Dose Groups) and Active Controlled (Eplerenone Group) Trial to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 5 Oral Doses of BI 690517 Over 28 Days in Female and Male Patients With Diabetic Nephropathy

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 31 Jul 2017

At a glance

  • Drugs BI 690517 (Primary) ; Eplerenone
  • Indications Diabetic nephropathies
  • Focus Adverse reactions
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 27 Jun 2017 Planned initiation date changed from 19 Jul 2017 to 21 Aug 2017.
    • 12 Jun 2017 Planned initiation date changed from 21 Aug 2017 to 19 Jul 2017.
    • 30 May 2017 Planned initiation date changed from 12 Jul 2017 to 21 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top